MEN1 and acute myeloid leukemia: Thus, combined use of immunoproteasome- and Menin-inhibitors facilitates efficient drug targeting of oncogenic transcriptional networks in AML (Fig. 8) and provides the opportunity for improved reduction of disease burden and preserved activity against MEN1-mutated clones to prevent resistance to targeted epigenetic therapies.